MX2022013649A - Métodos para identificar moduladores de la ruta de il-17. - Google Patents

Métodos para identificar moduladores de la ruta de il-17.

Info

Publication number
MX2022013649A
MX2022013649A MX2022013649A MX2022013649A MX2022013649A MX 2022013649 A MX2022013649 A MX 2022013649A MX 2022013649 A MX2022013649 A MX 2022013649A MX 2022013649 A MX2022013649 A MX 2022013649A MX 2022013649 A MX2022013649 A MX 2022013649A
Authority
MX
Mexico
Prior art keywords
pathway
methods
detecting
identifying modulators
modulate
Prior art date
Application number
MX2022013649A
Other languages
English (en)
Inventor
Steven Goldberg
Xuejun Liu
Leon-Tabaldo Aimee Rose De
Xiaohua Xue
Katherine Y Blain
Anne M Fourie
Rose Luna-Roman
Jr Michael Angelo Rodriguez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022013649A publication Critical patent/MX2022013649A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Transmitters (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos para identificar agentes que modulan la ruta de interleucina-17 (IL-17). Dichos métodos usan la detección de un nivel de factor estimulante de colonias de granulocitos (G-CSF) en un sobrenadante celular y/o la detección de un nivel de expresión de un gen o un panel de genes de una célula tratada con un agente. También se describen sondas capaces de detectar un gen o panel de genes y kits para identificar agentes que modulan la ruta de IL-17.
MX2022013649A 2020-04-30 2021-04-28 Métodos para identificar moduladores de la ruta de il-17. MX2022013649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017960P 2020-04-30 2020-04-30
PCT/IB2021/053516 WO2021220182A1 (en) 2020-04-30 2021-04-28 Methods of identifying modulators of the il-17 pathway

Publications (1)

Publication Number Publication Date
MX2022013649A true MX2022013649A (es) 2023-02-01

Family

ID=75787156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013649A MX2022013649A (es) 2020-04-30 2021-04-28 Métodos para identificar moduladores de la ruta de il-17.

Country Status (9)

Country Link
US (1) US20230167497A1 (es)
EP (1) EP4143342A1 (es)
JP (1) JP2023525234A (es)
KR (1) KR20230017211A (es)
CN (1) CN115735009A (es)
CA (1) CA3181418A1 (es)
IL (1) IL297689A (es)
MX (1) MX2022013649A (es)
WO (1) WO2021220182A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006214384A1 (en) * 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
BRPI0908312A2 (pt) * 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2016044189A1 (en) * 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists

Also Published As

Publication number Publication date
KR20230017211A (ko) 2023-02-03
CN115735009A (zh) 2023-03-03
CA3181418A1 (en) 2021-11-04
WO2021220182A1 (en) 2021-11-04
JP2023525234A (ja) 2023-06-15
US20230167497A1 (en) 2023-06-01
EP4143342A1 (en) 2023-03-08
IL297689A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
PH12020551261A1 (en) Il-15 conjugates and uses thereof
MX2022006536A (es) Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderan al tratamiento con un inhibidor de fgfr.
MX2019010196A (es) Composiciones y métodos para la inhibición de proteínas específicas del linaje.
WO2020113194A3 (en) Methods for treatment using adoptive cell therapy
MX2022013649A (es) Métodos para identificar moduladores de la ruta de il-17.
RS52932B (en) K-RAS AND B-RAF MUTATIONS AND ANTI-EGFR ANTIBODY TREATMENT
EP4085919A3 (en) Compositions and methods to treat cancer
MX2012013776A (es) Prueba e inspeccion virtual de una soldadura virtual.
EP4235189A3 (en) Additively manufactured heaters for air data probes
MX2020006901A (es) Composiciones de pares de bases no naturales y procedimientos de uso.
WO2017132291A8 (en) Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof
HK1107778A1 (en) Sodium stibogluconate and il-2 for treating cancer
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
MX2022008214A (es) Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
Trebska-McGowan et al. TGF-β alters the proportion of infiltrating immune cells in a pancreatic ductal adenocarcinoma
Sansone et al. Resident didactic education in borderline personality disorder: is it sufficient?
WO2022129637A8 (en) T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2018208584A3 (en) REFRESHMENT IN MEMORY BASED ON A DEFINED MARGIN
TW200727059A (en) Electro phoretic display device and driving method of the same
BR112021019365A2 (pt) Métodos para identificar um indivíduo que tem câncer, para selecionar uma terapia, para identificar uma interação proteína-proteína e para identificar um modulador, métodos de tratamento de um indivíduo com câncer, de identificação, de seleção de uma terapia e de identificação de um modulador, coleções de polipeptídeos, de vetores e de células e moduladores isolados
WO2023114785A3 (en) Three-dimensional bio-engineered lymphoid organs and organoids for cell-based therapies
Rao et al. Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients
IL285806A (en) Increasing the viability of gamma-delta cells to produce cell compounds for therapeutic use
Suh et al. Correction: Evaluating mobile services using integrated weighting approach and fuzzy VIKOR
WO2015051166A3 (en) Use of cox-3 binding molecules for modulating autophagy